Actinium Reports Positive Results for Leukemia Candidate

November 1, 2022

Actinium has announced positive results from its phase 3 trial of lomab-B as a conditioning regimen prior to a bone marrow transplant (BMT) to treat acute myeloid leukemia in patients over age 55 with relapsed or drug-resistant disease.

The investigational radiotherapy rapidly depletes blood cancer, immune and bone marrow stem cells, enabling the patient to tolerate the transplant. In the multi-center trial, the company said it met its primary endpoint of complete remission at six months compared to conventional care.

Actinium plans to submit a Biologics License Application for the drug, which already has been granted an Orphan Drug designation.

View today's stories